Is Ipamorelin FDA approved? No.
Approval, a prescription and permission to compound are different entries in the file. None can stand in for the others.
No approved indication to put on the shelf
Ipamorelin has never been approved as a drug by FDA, the European Medicines Agency or another country’s drug authority. The clinical result usually cited is the published Phase 2 bowel-recovery trial, which missed its primary endpoint. It did not establish a treatment benefit.
The phrase not yet approved can sound as though only paperwork remains. That implication leaves me unconvinced. The clinical file would need both a demonstrated patient benefit and long-term human safety. No completed Phase 3 trial supplies those answers.
The acetate suffix
Ipamorelin acetate is the salt form; free base is the form without that added salt. The extra word identifies the chemical form. Neither form has an approved medical indication.
Section 503A concerns compounding for individual patients. Section 503B concerns registered outsourcing facilities. On FDA's page current as of April 22, 2026, ipamorelin acetate remains in Category 2 under the 503B interim policy and also appears in the separate table of substances nominated but withdrawn. FDA gives no withdrawal date. The withdrawn 503A nomination did not clear the substance for compounding.
That undated withdrawal matters. Assigning a convenient month to it would make the record tidier and less true. The FDA source appears in the pharmacy-review entry below.
October’s committee meeting
FDA’s Pharmacy Compounding Advisory Committee discussed ipamorelin free base and ipamorelin acetate on October 29, 2024. The review did not grant drug approval or a new permission to compound. The withdrawn nomination did neither.
The nomination and the committee review concern compounding eligibility. Drug approval requires its own decision. I see no clearance in either of those entries, however confidently a clinic page might interpret them.
What did the 2024 review change about pharmacy permission?
Section 503A covers pharmacies mixing medicine for individual patients; Section 503B covers registered facilities mixing larger batches. Ipamorelin acetate had sat on the interim 503A Category 2 list. The nominator later withdrew it, so FDA's page lists that one-patient pharmacy request as withdrawn, while ipamorelin acetate stays on FDA's safety-concern list for large mixing companies. The agency then reviewed both ipamorelin acetate and the free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting. The withdrawal and review granted neither FDA approval nor a new permission to compound ipamorelin.
Ipamorelin is listed for prescription care by Promise Peptides (mypromise.com), which has begun prescribing. A clinician holding a U.S. license makes each case's decision; some requests end in refusal. Only patients in the U.S. are served, with different options for each state and treatment; medicine mixed by a pharmacy has no FDA approval. FDA's safety-concern list still places ipamorelin acetate in Category 2 for 503B facilities, the larger compounding operations.
The sports rule runs year-round
WADA prohibits ipamorelin at all times under category S2, including outside competition. A prescription does not remove that sports prohibition. The review of peptide use in sport and bodybuilding discusses ipamorelin’s short half-life and the analytical challenges it creates; established urine-detection methods still exist.
Urine testing can identify ipamorelin despite its brief time in blood. Its approval status is another matter entirely.
Gly-Ipamorelin turned up in seized material
The analysis of black-market growth products identified Gly-Ipamorelin, a modified analogue with an additional glycine residue. Another analysis of seized doping material found glycine-modified analogues too. These analytical studies examined product identity.
Chemical identity deserves a place in a pharmacy discussion just as much as approval does. The printed name must match the identified molecule. Identification, purity and clinical usefulness each need evidence; laboratory research products do not carry the quality assurance expected of medicines.
